Elevance Health Inc. reported its financial results for the third quarter of 2024, revealing a significant shortfall in earnings per share $(EPS)$, missing expectations by $1.33, or 13.7%, due to elevated medical costs in its Medicaid business. As a result, the company has revised its EPS guidance for 2024 downward from $37.20 to $33.00, reflecting an 11.3% decrease, anticipating continued challenges in its Medicaid segment. Following these disclosures, the price of Elevance common stock fell sharply by $52.61 per share, closing at $444.35 on October 17, 2024. The company had previously indicated on July 17, 2024, that it expected an increase in Medicaid utilization for the second half of the year, which led to a stock price decrease of $32.21 per share at that time. Elevance continues to face operational challenges associated with the redetermination process of Medicaid eligibility, which has impacted its financial performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.